Novel options for the treatment of castration-resistant prostate cancer
Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benef...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2012
|
| In: |
World journal of urology
Year: 2012, Volume: 30, Issue: 4, Pages: 495-503 |
| ISSN: | 1433-8726 |
| DOI: | 10.1007/s00345-011-0796-7 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1007/s00345-011-0796-7 Verlag, Volltext: https://link.springer.com/article/10.1007/s00345-011-0796-7 
|
| Author Notes: | Carsten-H. Ohlmann, Axel S. Merseburger, Henrik Suttmann, David Schilling, Lutz Trojan, Carsten Kempkensteffen, Stefan Corvin, Michael J. Mathers, Patrick J. Bastian |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576851176 | ||
| 003 | DE-627 | ||
| 005 | 20220814174415.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180626s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00345-011-0796-7 |2 doi | |
| 035 | |a (DE-627)1576851176 | ||
| 035 | |a (DE-576)506851176 | ||
| 035 | |a (DE-599)BSZ506851176 | ||
| 035 | |a (OCoLC)1341012791 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ohlmann, Carsten-Henning |e VerfasserIn |0 (DE-588)1022541129 |0 (DE-627)716997908 |0 (DE-576)361868138 |4 aut | |
| 245 | 1 | 0 | |a Novel options for the treatment of castration-resistant prostate cancer |c Carsten-H. Ohlmann, Axel S. Merseburger, Henrik Suttmann, David Schilling, Lutz Trojan, Carsten Kempkensteffen, Stefan Corvin, Michael J. Mathers, Patrick J. Bastian |
| 264 | 1 | |c 2012 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 20 November 2011 | ||
| 500 | |a Gesehen am 26.06.2018 | ||
| 520 | |a Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials. | ||
| 700 | 1 | |a Merseburger, Axel S. |d 1976- |e VerfasserIn |0 (DE-588)124698417 |0 (DE-627)36437084X |0 (DE-576)294454268 |4 aut | |
| 700 | 1 | |a Suttmann, Henrik |d 1972- |e VerfasserIn |0 (DE-588)122891538 |0 (DE-627)70608117X |0 (DE-576)293466130 |4 aut | |
| 700 | 1 | |a Schilling, David Alexander |d 1974- |e VerfasserIn |0 (DE-588)124804985 |0 (DE-627)36643196X |0 (DE-576)294511830 |4 aut | |
| 700 | 1 | |a Trojan, Lutz |d 1973- |e VerfasserIn |0 (DE-588)124059856 |0 (DE-627)706523571 |0 (DE-576)294001492 |4 aut | |
| 700 | 1 | |a Kempkensteffen, Carsten |d 1973- |e VerfasserIn |0 (DE-588)124276407 |0 (DE-627)085754994 |0 (DE-576)294098461 |4 aut | |
| 700 | 1 | |a Corvin, Stefan |d 1966- |e VerfasserIn |0 (DE-588)121011119 |0 (DE-627)08102889X |0 (DE-576)182703916 |4 aut | |
| 700 | 1 | |a Mathers, Michael J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bastian, Patrick J. |d 1973- |e VerfasserIn |0 (DE-588)122553152 |0 (DE-627)082013373 |0 (DE-576)293320659 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of urology |d Berlin : Springer, 1983 |g 30(2012), 4, Seite 495-503 |h Online-Ressource |w (DE-627)254910874 |w (DE-600)1463303-6 |w (DE-576)074754505 |x 1433-8726 |7 nnas |a Novel options for the treatment of castration-resistant prostate cancer |
| 773 | 1 | 8 | |g volume:30 |g year:2012 |g number:4 |g pages:495-503 |g extent:9 |a Novel options for the treatment of castration-resistant prostate cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00345-011-0796-7 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s00345-011-0796-7 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180626 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 124059856 |a Trojan, Lutz |m 124059856:Trojan, Lutz |d 60000 |d 63100 |e 60000PT124059856 |e 63100PT124059856 |k 0/60000/ |k 1/60000/63100/ |p 5 | ||
| 999 | |a KXP-PPN1576851176 |e 3013803592 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Ohlmann","given":"Carsten-Henning","roleDisplay":"VerfasserIn","display":"Ohlmann, Carsten-Henning","role":"aut"},{"family":"Merseburger","given":"Axel S.","display":"Merseburger, Axel S.","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Suttmann, Henrik","roleDisplay":"VerfasserIn","role":"aut","family":"Suttmann","given":"Henrik"},{"family":"Schilling","given":"David Alexander","roleDisplay":"VerfasserIn","display":"Schilling, David Alexander","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Trojan, Lutz","given":"Lutz","family":"Trojan"},{"roleDisplay":"VerfasserIn","display":"Kempkensteffen, Carsten","role":"aut","family":"Kempkensteffen","given":"Carsten"},{"roleDisplay":"VerfasserIn","display":"Corvin, Stefan","role":"aut","family":"Corvin","given":"Stefan"},{"roleDisplay":"VerfasserIn","display":"Mathers, Michael J.","role":"aut","family":"Mathers","given":"Michael J."},{"display":"Bastian, Patrick J.","roleDisplay":"VerfasserIn","role":"aut","family":"Bastian","given":"Patrick J."}],"title":[{"title_sort":"Novel options for the treatment of castration-resistant prostate cancer","title":"Novel options for the treatment of castration-resistant prostate cancer"}],"note":["Published online: 20 November 2011","Gesehen am 26.06.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"recId":"1576851176","name":{"displayForm":["Carsten-H. Ohlmann, Axel S. Merseburger, Henrik Suttmann, David Schilling, Lutz Trojan, Carsten Kempkensteffen, Stefan Corvin, Michael J. Mathers, Patrick J. Bastian"]},"origin":[{"dateIssuedDisp":"2012","dateIssuedKey":"2012"}],"id":{"eki":["1576851176"],"doi":["10.1007/s00345-011-0796-7"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"origin":[{"publisher":"Springer","dateIssuedKey":"1983","dateIssuedDisp":"1983-","publisherPlace":"Berlin ; Heidelberg"}],"id":{"issn":["1433-8726"],"eki":["254910874"],"zdb":["1463303-6"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"World journal of urology","title":"World journal of urology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 06.12.05","Teils ungezählte Beil.: Supplement"],"disp":"Novel options for the treatment of castration-resistant prostate cancerWorld journal of urology","language":["eng"],"recId":"254910874","pubHistory":["1.1983 -"],"part":{"volume":"30","text":"30(2012), 4, Seite 495-503","extent":"9","year":"2012","issue":"4","pages":"495-503"}}]} | ||
| SRT | |a OHLMANNCARNOVELOPTIO2012 | ||